Inezetamab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameInezetamab

Drug Alias NameAMG-994

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionMesothelin inhibitorsTumor necrosis factor receptor superfamily member 5 agonists

TargetsTumor necrosis factor receptor superfamily member 5Mesothelin

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[10]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A